Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Epizyme, Inc. (EPZM) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/08/2022 SC 13G/A PRIMECAP MANAGEMENT CO reports a 0% stake in Epizyme, Inc.
08/23/2022 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
08/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update"
08/05/2022 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
08/04/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/01/2022 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
08/01/2022 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
07/12/2022 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
07/12/2022 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
07/07/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
07/05/2022 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
06/28/2022 SC 13D/A RPI Finance Trust reports a 20.6% stake in Epizyme, Inc.
06/27/2022 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
06/27/2022 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
06/27/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
05/03/2022 CT ORDER Form CT ORDER - Confidential treatment order:
04/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/30/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/30/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update"
03/01/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/01/2022 10-K Annual Report for the period ended December 31, 2021
03/01/2022 8-K Quarterly results
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy